| abstract |
An improvement in a method of treating an HIV/AIDS infection in human patients in which the patient receives antiretroviral therapy and is consequently subjected to significant risk of developing the lipodystrophy syndrome in one or more of its characteristics. This risk is reduced, and pre-existing signs of such syndrome from past therapy can be substantially reversed, by the concurrent administration by a therapeutically effective mode of an essentially pure opiate receptor antagonist such as Naltrexone and Naloxone at a low level dosage. |